These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37379355)

  • 1. SARS-CoV-2 seroprevalence on the north coast of Peru: A cross-sectional study after the first wave.
    Moyano LM; Toledo AK; Chirinos J; Vilchez Barreto PMQ; Cavalcanti S; Gamboa R; Ypanaque J; Meza M; Noriega S; Herrera V; Bazan E; Requena A; Silva H; Burgos H; León-Jimenez F;
    PLoS Negl Trop Dis; 2023 Jun; 17(6):e0010794. PubMed ID: 37379355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 prevalence associated to low socioeconomic status and overcrowding in an LMIC megacity: A population-based seroepidemiological survey in Lima, Peru.
    Reyes-Vega MF; Soto-Cabezas MG; Cárdenas F; Martel KS; Valle A; Valverde J; Vidal-Anzardo M; Falcón ME; Munayco CV;
    EClinicalMedicine; 2021 Apr; 34():100801. PubMed ID: 33817611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High SARS-CoV-2 Seroprevalence in Rural Peru, 2021: a Cross-Sectional Population-Based Study.
    Moreira-Soto A; Pachamora Diaz JM; González-Auza L; Merino Merino XJ; Schwalb A; Drosten C; Gotuzzo E; Talledo M; Arévalo Ramirez H; Peralta Delgado R; Bocanegra Vargas S; Drexler JF
    mSphere; 2021 Dec; 6(6):e0068521. PubMed ID: 34817236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptoms and symptom clusters associated with SARS-CoV-2 infection in community-based populations: Results from a statewide epidemiological study.
    Dixon BE; Wools-Kaloustian K; Fadel WF; Duszynski TJ; Yiannoutsos C; Halverson PK; Menachemi N
    medRxiv; 2020 Oct; ():. PubMed ID: 33106813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study.
    Álvarez-Antonio C; Meza-Sánchez G; Calampa C; Casanova W; Carey C; Alava F; Rodríguez-Ferrucci H; Quispe AM
    Lancet Glob Health; 2021 Jul; 9(7):e925-e931. PubMed ID: 34022148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.
    Zamani M; Poustchi H; Mohammadi Z; Dalvand S; Sharafkhah M; Motevalian SA; Eslami S; Emami A; Somi MH; Yazdani-Charati J; Saki N; Karami M; Najafi F; Mohebbi I; Veisi N; Hormati A; Pourfarzi F; Ghadimi R; Ansari-Moghaddam A; Sharifi H; Roshandel G; Mansour-Ghanaei F; Joukar F; Shayanrad A; Eghtesad S; Niavarani A; Delavari A; Kaveh S; Feizesani A; Markarian M; Shafighian F; Sadjadi A; Darvishian M; Malekzadeh R
    BMC Public Health; 2022 May; 22(1):1031. PubMed ID: 35606743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.
    Struyf T; Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Leeflang MM; Spijker R; Hooft L; Emperador D; Domen J; Tans A; Janssens S; Wickramasinghe D; Lannoy V; Horn SRA; Van den Bruel A;
    Cochrane Database Syst Rev; 2022 May; 5(5):CD013665. PubMed ID: 35593186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study.
    Laxminarayan R; B CM; G VT; Arjun Kumar KV; Wahl B; Lewnard JA
    Lancet Infect Dis; 2021 Dec; 21(12):1665-1676. PubMed ID: 34399090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020.
    Díaz-Vélez C; Failoc-Rojas VE; Valladares-Garrido MJ; Colchado J; Carrera-Acosta L; Becerra M; Moreno Paico D; Ocampo-Salazar ET
    PeerJ; 2021; 9():e11210. PubMed ID: 33868828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Spijker R; Taylor-Phillips S; Adriano A; Beese S; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Dittrich S; Emperador D; Hooft L; Leeflang MM; Van den Bruel A;
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013652. PubMed ID: 32584464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.
    Struyf T; Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Leeflang MM; Spijker R; Hooft L; Emperador D; Domen J; Horn SRA; Van den Bruel A;
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013665. PubMed ID: 33620086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Fox T; Geppert J; Dinnes J; Scandrett K; Bigio J; Sulis G; Hettiarachchi D; Mathangasinghe Y; Weeratunga P; Wickramasinghe D; Bergman H; Buckley BS; Probyn K; Sguassero Y; Davenport C; Cunningham J; Dittrich S; Emperador D; Hooft L; Leeflang MM; McInnes MD; Spijker R; Struyf T; Van den Bruel A; Verbakel JY; Takwoingi Y; Taylor-Phillips S; Deeks JJ;
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013652. PubMed ID: 36394900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
    Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of anosmia, ageusia and age in community presentation of symptomatic and asymptomatic SARS-CoV-2 infection in Louisiana, USA; a cross-sectional prevalence study.
    Feehan AK; Fort D; Velasco C; Burton JH; Garcia-Diaz J; Price-Haywood EG; Sapp E; Pevey D; Seoane L
    Clin Microbiol Infect; 2021 Apr; 27(4):633.e9-633.e16. PubMed ID: 33421576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study.
    Beaumont A; Durand C; Ledrans M; Schwoebel V; Noel H; Le Strat Y; Diulius D; Colombain L; Médus M; Gueudet P; Mouly D; Aumaître H
    BMJ Open; 2021 Nov; 11(11):e053201. PubMed ID: 34815286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
    Pollán M; Pérez-Gómez B; Pastor-Barriuso R; Oteo J; Hernán MA; Pérez-Olmeda M; Sanmartín JL; Fernández-García A; Cruz I; Fernández de Larrea N; Molina M; Rodríguez-Cabrera F; Martín M; Merino-Amador P; León Paniagua J; Muñoz-Montalvo JF; Blanco F; Yotti R;
    Lancet; 2020 Aug; 396(10250):535-544. PubMed ID: 32645347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anosmia, ageusia, and other COVID-19-like symptoms in association with a positive SARS-CoV-2 test, across six national digital surveillance platforms: an observational study.
    Sudre CH; Keshet A; Graham MS; Joshi AD; Shilo S; Rossman H; Murray B; Molteni E; Klaser K; Canas LD; Antonelli M; Nguyen LH; Drew DA; Modat M; Pujol JC; Ganesh S; Wolf J; Meir T; Chan AT; Steves CJ; Spector TD; Brownstein JS; Segal E; Ourselin S; Astley CM
    Lancet Digit Health; 2021 Sep; 3(9):e577-e586. PubMed ID: 34305035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study.
    Sauré D; O'Ryan M; Torres JP; Zuñiga M; Soto-Rifo R; Valiente-Echeverría F; Gaete-Argel A; Neira I; Saavedra V; Acevedo ML; Archila C; Acuña F; Rain M; Basso LJ
    Lancet Microbe; 2023 Mar; 4(3):e149-e158. PubMed ID: 36716754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
    Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
    Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seroprevalence of SARS-CoV-2 and assessment of epidemiologic determinants in Portuguese municipal workers.
    Barros Ferreira N; Pereira H; Pereira AM; Azevedo LF; Santos M; Maranhão P; Correia R; Fonseca JA; Canedo P; da Costa Pereira A; Sousa-Pinto B
    Int J Occup Med Environ Health; 2022 Jun; 35(3):297-307. PubMed ID: 35142298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.